<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CALFACTANT</span><br/>(cal-fac'tant)<br/><span class="topboxtradename">Infasurf<br/></span><b>Classifications:</b> <span class="classification">lung surfactant</span><br/><b>Prototype: </b>Beractant<br/><b>Pregnancy Category: </b>Not applicable<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>35 mg/mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Pulmonary surfactant. Lowers the surface tension on alveolar surfaces during respiration and stabilizes the alveoli against
         collapse at resting pressure. Deficiency of surfactant causes respiratory disease syndrome (RDS) in premature infants.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectively relieves and prevents RDS in neonates.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of RDS in infants at high risk for RDS.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Nosocomial infections.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention &amp; Treatment of RDS</span><br/><span class="rdage">Infant:</span> <span class="rdroute">Intratracheal</span> 3 mL/kg of birth weight administered through an endotracheal tube q12h times 3 doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intratracheal</span><br/><ul>
<li>Swirl vial to disperse suspension; do not dilute and DO NOT SHAKE. Withdraw with 20-gauge or larger needle. Avoid excess foaming.
            Instill into the endotracheal tube, preferably within 30 min of birth.
         </li>
<li>Stop administration of calfactant if reflux into endotracheal tube occurs as indicated by cyanosis, bradycardia, or other
            signs of airway obstruction.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span>
<span class="speceff-common">Bradycardia</span>. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Cyanosis, airway obstruction, reflux of surfactant</span> into endotracheal tube. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorbs rapidly to air; liquid interface of lung surface. No other human pharmacokinetic information available. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely during and after administration; adjustments in oxygen therapy and ventilator pressures are usually needed.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>This drug will help baby to breathe properly and support normal respiratory function.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>